10 pharmacovigilance experts
A head-of-function title is the norm among these pharmacovigilance experts, and five are vice presidents over safety and pharmacovigilance at Corcept Therapeutics, Eledon, Keenova, Adverum and Ascendis; others hold operations, quality and QPPV titles at Bristol Myers Squibb, UCB, Chiesi Group and argenx. Their records suit a team standing up drug safety for a product in trials, sorting out individual case processing, or taking on QPPV duties in Europe.
Professionals to explore
Alexander Kluczka
LinkedInExperience: Head of Pharmacovigilance Operations and Systems · Bristol Myers Squibb
$943 per 30-minute call
Alexander Kluczka has been Head of Pharmacovigilance Operations and Systems at Bristol Myers Squibb since March 2024. At Bayer, Alexander held Global Pharmacovigilance, Head TA Oncology - ICSR Processing (2012-2024), Global Medical Affairs - Head of Global Operations and Coordination (2010-2012) and Global Pharmacovigilance - TA Head Specialized Therapeutics - Risk Management (2007-2010), and was Pharmacovigilance Country Head and UK QPPV at Schering Health Care Limited (2004-2007). A fit for case processing and PV systems questions.
Is this you? Claim your profile and get paid for calls.
Ankur Makadia
LinkedInExperience: Ankur Makadia's titles · UCB are Head of Pharmacovigilance Quality; Former Head of International Pharmacovigilance Operations & Americas · UCB
$673 per 30-minute call
Ankur Makadia's titles at UCB are Head of Pharmacovigilance Quality since September 2024, Head of International Pharmacovigilance Operations & Americas (2022-2025), Head of Safety Data Insights (2018-2022), Head of Neurology Patient Safety Unit (2015-2018) and Director Product Safety Lead (2012-2015). The international operations role covered oversight of International Pharmacovigilance Operations, QPPV Operations and PV for the Americas region.
Is this you? Claim your profile and get paid for calls.
Barbara Del Carlo
LinkedInExperience: Former Head of Global Pharmacovigilance Operations, Deputy EU UK QPPV · Chiesi Group
$673 per 30-minute call
Since December 2022, Barbara Del Carlo has been Deputy EU UK QPPV at argenx, currently acting as Global Regional Head with tasks that include compliance with local, regional and global safety regulatory requirements. At Chiesi Group, Barbara was Head of Global Pharmacovigilance Operations, Deputy EU UK QPPV (2015-2022) and Country PV Manager, Deputy EU QPPV (2012-2015), and was EU QPPV at Kedrion Biopharma (2006-2011).
Is this you? Claim your profile and get paid for calls.
Deepa Venkataraman
LinkedInExperience: Vice President, Head of Global Patient Safety and Pharmacovigilance · Corcept Therapeutics
$1,010 per 30-minute call
Deepa Venkataraman is Vice President, Head of Global Patient Safety and Pharmacovigilance at Corcept Therapeutics (since June 2022). At Summit Therapeutics, Deepa was SVP, Head of Global Patient Safety, Pharmacovigilance and Quality Assurance (2021-2022) and SVP, Head of Global Patient Safety and Pharmacovigilance (February to June 2021); at AbbVie, Head of Global Case Management, Medical Coding and Medical Safety Review, PPS (2020-2021) and Senior Director, Section Head, PPS (2019-2020).
Is this you? Claim your profile and get paid for calls.
Donna Valencia
LinkedInExperience: Vice President, Head of Pharmacovigilance · Adverum Biotechnologies
$673 per 30-minute call
Donna Valencia has been Vice President, Head of Pharmacovigilance at Adverum Biotechnologies since March 2025, after five months as Executive Director, Head of Pharmacovigilance there. Earlier titles are Vice President, Head of Drug Safety at Immune-Onc Therapeutics (2022-2024) and Vice President and Senior Director, Head of Patient Safety and Epidemiology at Sio Gene Therapies (2017-2022). Donna cites "establishing and managing in-house pharmacovigilance functions, particularly in oncology, neurology, and advanced therapies."
Is this you? Claim your profile and get paid for calls.
Laura Lindsey
LinkedInExperience: Vice President & Global Head, Pharmacovigilance & Risk Management · Keenova
$808 per 30-minute call
Laura Lindsey has held Vice President & Global Head, Pharmacovigilance & Risk Management at Keenova since 2016, and was Head, Global Pharmacovigilance Operations, Compliance & Training at GE HealthCare (2012-2016). Laura also worked as an Independent Consultant at LJL Clinical Services, LLC (2005-2012) and Associate Director, Drug Safety at Celgene Corporation (1998-2001), and describes experience across case processing and aggregate reporting.
Is this you? Claim your profile and get paid for calls.
Lilliam Fernandes
LinkedInExperience: Former Head of Global Pharmacovigilance · US WorldMeds
$539 per 30-minute call
Lilliam Fernandes became Head of Global Pharmacovigilance at US WorldMeds in June 2026, after serving there as Director for Clinical Safety and Pharmacovigilance (2025-2026). Lilliam held that same director title at Adaptimmune (2016-2025), was Associate Director For Clinical Safety and Pharmacovigilance there (2012-2016) and a Clinical Scientist at Pfizer (2007-2012), a fit for questions on clinical-stage safety work and moving into a global head role.
Is this you? Claim your profile and get paid for calls.
Mandeep Singh
LinkedInExperience: VP, Global Head of Pharmacovigilance and Drug Safety · Ascendis Pharma
$1,010 per 30-minute call
Mandeep Singh is VP, Global Head of Pharmacovigilance and Drug Safety at Ascendis Pharma (since June 2021) and was Senior Director, Pharmacovigilance Safety Evaluation there (2020-2021). At Genentech, Mandeep held Director, Head PV Clinical Group, US Drug Safety (2018-2020), Director, Head of Case Management (2016-2018) and Medical Science Director (2015), which fits questions on case management and safety evaluation.
Is this you? Claim your profile and get paid for calls.
Priya Nandi
LinkedInExperience: Executive Director, Drug Safety & Pharmacovigilance · Coherus Oncology
$539 per 30-minute call
Executive Director, Drug Safety & Pharmacovigilance at Coherus Oncology since July 2023, Priya Nandi was Director Pharmacovigilance (2018-2023) and Associate Director, Pharmacovigilance (2015-2018) at Clovis Oncology and Assistant Director, US Pharmacovigilance Medical Records Team at Bayer (2012-2014). In Priya's own words, Priya is "proficient in setting up a global PV system and building PV team (s)", which suits questions on building the function at an oncology company.
Is this you? Claim your profile and get paid for calls.
Sepideh Habibi, MD
LinkedInExperience: VP, Head of Safety and Pharmacovigilance · Eledon Pharmaceuticals, Inc.
$673 per 30-minute call
As VP, Head of Safety and Pharmacovigilance at Eledon Pharmaceuticals, Inc. since February 2025, Sepideh Habibi oversees PV operation, PV compliance and medical safety, including PV governance. Sepideh also held Global Head of Pharmacovigilance and Risk Management at CRISPR Therapeutics (2020-2025), Head of Pharmacovigilance at REGENXBIO (2019-2020) and Vice President, Global Head of Drug Safety and Pharmacovigilance at Sucampo Pharmaceuticals, Inc. (2011-2018).
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For owning the whole safety function, pick one of the five vice presidents: Deepa Venkataraman, Sepideh Habibi, Laura Lindsey, Donna Valencia or Mandeep Singh. Case processing, PV quality and QPPV questions fit Alexander Kluczka, Ankur Makadia and Barbara Del Carlo, while Priya Nandi and Lilliam Fernandes have spent long stretches in pharmacovigilance director roles at Clovis Oncology and Adaptimmune.
Questions to take into the conversation
- 01At what point before approval should a company bring individual case safety report processing in-house rather than leave it with a vendor?
- 02What does a QPPV need from the global pharmacovigilance team to meet EU and UK obligations?
- 03How should signal detection and aggregate reporting be staffed when a product moves from trials to the market?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.